Mouse Anti-MAP4K2 Recombinant Antibody (CBLG1-3230) (CBMAB-G6371-LY)

This product is antibody recognizes MAP4K2. The antibody CBLG1-3230 immunoassay techniques such as: WB.
See all MAP4K2 antibodies

Datasheet

Summary

Host Animal

Mouse

Specificity

Human

Clone

CBLG1-3230

Antibody Isotype

IgG

Application

Basic Information

Specificity

Human

Antibody Isotype

IgG

Clonality

Monoclonal

Application Notes

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format

Liquid

Purity

> 95% Purity determined by SDS-PAGE.

Storage

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

Target

Full Name

MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 2

Introduction

The protein encoded by this gene is a member of the serine/threonine protein kinase family. Although this kinase is found in many tissues, its expression in lymphoid follicles is restricted to the cells of germinal centre, where it may participate in B-cell differentiation. This kinase can be activated by TNF-alpha, and has been shown to specifically activate MAP kinases. This kinase is also found to interact with TNF receptor-associated factor 2 (TRAF2), which is involved in the activation of MAP3K1/MEKK1. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2015]

Entrez Gene ID

5871

UniProt ID

Q12851

Alternative Names

Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2; MAPK/ERK Kinase Kinase Kinase 2; MEK Kinase Kinase 2; EC 2.7.11.1; MEKKK 2; RAB8IP; GCK; B Lymphocyte Serine/Threonine Protein Kinase; B Lymphocyte Serine/Threonine-Protein Kinase;

Function

Serine/threonine-protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Acts as a MAPK kinase kinase kinase (MAP4K) and is an upstream activator of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway and to a lesser extent of the p38 MAPKs signaling pathway. Required for the efficient activation of JNKs by TRAF6-dependent stimuli, including pathogen-associated molecular patterns (PAMPs) such as polyinosine-polycytidine (poly(IC)), lipopolysaccharides (LPS), lipid A, peptidoglycan (PGN), or bacterial flagellin. To a lesser degree, IL-1 and engagement of CD40 also stimulate MAP4K2-mediated JNKs activation. The requirement for MAP4K2/GCK is most pronounced for LPS signaling, and extends to LPS stimulation of c-Jun phosphorylation and induction of IL-8. Enhances MAP3K1 oligomerization, which may relieve N-terminal mediated MAP3K1 autoinhibition and lead to activation following autophosphorylation. Mediates also the SAP/JNK signaling pathway and the p38 MAPKs signaling pathway through activation of the MAP3Ks MAP3K10/MLK2 and MAP3K11/MLK3. May play a role in the regulation of vesicle targeting or fusion. regulation of vesicle targeting or fusion.

Biological Process

Immune responseManual Assertion Based On ExperimentTAS:ProtInc
Innate immune responseIEA:UniProtKB-KW
Intracellular signal transductionManual Assertion Based On ExperimentIDA:UniProtKB
JNK cascadeManual Assertion Based On ExperimentTAS:ProtInc
Positive regulation of JNK cascadeManual Assertion Based On ExperimentIDA:UniProtKB
Positive regulation of JUN kinase activityManual Assertion Based On ExperimentIDA:UniProtKB
Protein phosphorylationManual Assertion Based On ExperimentIDA:UniProtKB
Vesicle targetingIEA:Ensembl

Cellular Location

Cytoplasm
Basolateral cell membrane
Golgi apparatus membrane

PTM

Polyubiquitinated through 'Lys-48'-polyubiquitin chains, allowing proteasomal turnover. Ubiquitination requires the kinase activity of MAP4K2/GCK.
Autophosphorylated in response to tumor necrosis factor (TNF), endotoxins or pro-inflammatory stimuli. Autophosphorylation leads to activation.

References

Seo, G., Mckinley, J., & Wang, W. (2023). MAP4K2 connects the Hippo pathway to autophagy in response to energy stress. Autophagy, 1-3.

Ma, C., Shi, Z. H., Han, X. Y., Liu, C., Yan, B., & Du, J. L. (2022). Targeting circRNA-MAP4K2 for the treatment of diabetes-induced retinal vascular dysfunction. Aging (Albany NY), 14(15), 6255.

Li, S., Fu, J., Yang, J., Ma, H., Mapara, M. Y., Marcireau, C., & Lentzsch, S. (2021). MAP4K2 Silencing Overcomes IMiDs-Resistance in Multiple Myeloma. Blood, 138, 2662.

Li, S., Fu, J., Xu, X., Deng, S., Landry, D., Mapara, M., & Lentzsch, S. (2019). Treatment of RAS-Mutated Multiple Myeloma by Targeting MAP4K2. Clinical Lymphoma, Myeloma and Leukemia, 19(10), e131-e132.

Q & As

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Review & reward

Have you used Mouse Anti-MAP4K2 Recombinant Antibody (CBLG1-3230)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Protocols

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Associated Products

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Datasheet
SDS
Request for COA

Request bulk or custom quote

Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email: